<DOC>
	<DOCNO>NCT01601600</DOCNO>
	<brief_summary>The purpose Proof Concept study determine effect BYM338 skeletal muscle volume , mass , strength patient function ( gait speed ) non-demented elderly adult sarcopenia mobility limitation . In addition , study generate data safety , tolerability , pharmacokinetics BYM338 old adult response additional physical function measure population . Furthermore , extend study duration provide information stability BYM-induced change skeletal muscle patient function subgroup old population .</brief_summary>
	<brief_title>A Multi-center Study Assess Effects BYM338 Skeletal Muscle Sarcopenic Adults</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Antibodies , Blocking</mesh_term>
	<criteria>1 . Men woman age 65 old difficulty stand chair walk long 10 minute flat surface climb flight stair . 2 . Written informed consent must obtain laboratory physical assessment perform establish eligibility . Answering initial question qualification , whether person phone require write consent . 3 . At onsite screening , candidate gait speed measure 4 meter &lt; 1.0 m/s ≥0.6 m/s . 4 . Appendicular skeletal muscle index ( skeletal muscle kg/ height m2 ) DXA ≤ 7.25 kg/m2 men ≤ 5.67 kg/m2 woman assess screen gait speed criterion # 3 met . 5 . At screen baseline , vital sign ( systolic diastolic blood pressure pulse rate ) assess supine position follow assessment standing within three ( 3 ) minute change position . Investigators guide follow range supine measurement position change : oral body temperature 35.037.5 °C systolic blood pressure , 80160 mm Hg reduction &gt; 20mmHg diastolic blood pressure , 5090 mm Hg reduction &gt; 10mmHg pulse rate , 50 100 bpm 6 . Patients must weigh least 35 kg participate study , must body mass index ( BMI ) within range 18 32 kg/m2 , inclusive . ( See Appendix 4 ) protocol BMI range . 7 . Be able communicate well investigator , understand comply requirement study . 1 . Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever longer ; longer require local regulation , limitation participation investigational trial base local regulation . 2 . History hypersensitivity antibody . 3 . A history clinically significant ECG abnormality , , opinion investigator , may indicate active cardiac disease . 4 . History malignancy organ system ( localize nonmelanomatous cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . 5 . Diseases cancer know cause cachexia muscle atrophy , include limited congestive heart failure stage , COPD , chronic kidney disease ( estimate GFR &lt; 30 mL/min use MDRD equation ) , rheumatoid arthritis , primary myopathy , stroke , HIV infection , tuberculosis chronic infection , uncontrolled diabetes mellitus . 6 . Diseases know cause malabsorption protein energy , include inflammatory bowel disease , celiac disease , short bowel syndrome , pancreatic insufficiency , etc . 7 . Liver disease liver injury indicate abnormal liver function test SGOT ( AST ) , SGPT ( ALT ) , γGT , alkaline phosphatase , serum bilirubin ( except Gilbert 's Disease ) . The Investigator guide follow criterion : Any single transaminase list may exceed 3x upper limit normal ( ULN ) . If total bilirubin concentration increase 1.5 x ULN , total bilirubin differentiate direct indirect react bilirubin . In case , serum bilirubin exceed value 1.6 mg/dL ( 27 μmol/L ) . 8 . Use prescription drug know affect muscle mass , include androgen supplement , antiandrogens ( LHRH agonist ) , antiestrogens ( tamoxifen , etc . ) recombinant human growth hormone ( rhGH ) , insulin , oral beta agonist , megestrol acetate , dronabinol , etc . 9 . Donation loss 400 mL blood within eight ( 8 ) week prior initial dosing , longer required local regulation . 10 . Plasma donation ( &gt; 250 mL ) within 14 day prior first dosing . 11 . Hemoglobin concentration 11.0 g/dL screening . 12 . Significant illness within two ( 2 ) week prior initial dosing . 13 . Patients know claustrophobia , presence pacemaker and/or ferromagnetic material body would prohibit administration MRI assessment . 14 . Patient smoke one cigarette , pipe cigar month</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>